FDA Approves Labcorp's Companion Diagnostic for Melanoma Targeted Therapy
LH sits 29% above its 52-week low of $244.52.
Summary
Labcorp received FDA approval for PGDx Elio Tissue Complete CDx, a companion diagnostic that identifies advanced melanoma patients with BRAF V600E/K variants who may benefit from targeted therapies. This expands Labcorp's oncology diagnostics portfolio, following recent launches like NASHnext and ColoSense. The approval strengthens the company's position in precision medicine and could drive incremental testing volume. Shares edged up 0.13% pre-market, trading near a 52-week high.
At the time of this announcement, LH was trading at $315.34 on NYSE in the Life Sciences sector, with a market capitalization of approximately $25.9B. The 52-week trading range was $244.52 to $319.94. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: dpa-AFX.